Referencias

1. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705. | CrossRef | PubMed
2. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005 Mar 1;111(8):1012-8. Epub 2005 Feb 21. | CrossRef | PubMed
3. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007 Jul-Aug;1(4):264-77. | CrossRef | PubMed
4. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008 Mar; 26(3):589-99. | CrossRef | PubMed
5. Uresin Y, Taylor A, Kilo C, et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens. 2006:24(Suppl 4):S82,p4.269.
6. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan;25(1):217-26. | CrossRef | PubMed
7. Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich). 2007 Oct;9(10):742-50. | CrossRef | PubMed
8. Mitchell J, Oh BH, Herron J, et al. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006;8(5): A93 P-209.
9. Sica D, Gradman AH, Lederballe O. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006;27(Suppl): 121 P-797
10. Palatini P, Jung W, Shlyakhto E. Blood pressure reduction following a simulated missed dose of aliskiren, irbesartan, or ramipril: a comparative ambulatory blood pressure monitoring study. Resumen aceptado en Congreso ASH, New Orleans LA, USA, 14 al 17 de mayo de 2008
11. Calhoun D, Chrysant SG, Villamil A. The novel oral renin inhibitor aliskiren decreases plasma renin activity (PRA) and neutralizes hydrochlorothiazide-induced renin system activation in hypertensive patients. J Clin Hypertens 2006; 8(5): A77 P-168
12. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008 Jun;73(12):1419-25. Epub 2008 Mar 12. | CrossRef | PubMed
13. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17-24. | CrossRef | PubMed